Physician profile
Arthur Rose
NPI 1497736235
$1,937.17
in general payments reported to CMS, 2019-2025
27 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.92 · 2020: $124 · 2021: $757 · 2022: $407 · 2023: $199 · 2024: $286 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $390.53 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $228.57 | 2021-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $201.79 | 2020-2022 | |
| Esperion Therapeutics, INC. | $145.31 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.76 | 2021-2024 | Synjardy, Jardiance, Ofev |
| Astellas Pharma US INC | $96.94 | 2021-2023 | Myrbetriq, Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.18 | 2021-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $69.19 | 2020-2023 | Shingrix, Arexvy |
| Amgen INC. | $66.38 | 2020-2022 | |
| Abbvie INC. | $63.65 | 2024-2025 | |
| Inspire Medical Systems, INC. | $60.17 | 2024 | Inspire |
| Vanda Pharmaceuticals INC. | $55.97 | 2021 | |
| Almatica Pharma LLC | $36.15 | 2022 | |
| Pfizer INC. | $35.11 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $32.97 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $30.60 | 2022 | |
| Bioventus LLC | $29.64 | 2020 | |
| Mannkind Corporation | $25.92 | 2025 | |
| Madrigal Pharmaceuticals | $25.01 | 2024 | Resmetirom |
| Bayer Healthcare Pharmaceuticals INC. | $24.82 | 2025 | |
| Dynavax Technologies Corporation | $23.38 | 2022 | |
| Exact Sciences Corporation | $20.02 | 2024 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $17.44 | 2023 | Unithroid |
| Takeda Pharmaceuticals U.S.A., INC. | $16.99 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $16.24 | 2024 | Opsumit, Uptravi |
| Teva Pharmaceuticals USA, INC. | $15.53 | 2021 | |
| Qol Medical, LLC | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.